Ana Fraga
Papers
1
Total Citations
126
H-Index
1
About
Dr. Ana Fraga is a leading figure in translational proteomics and clinical mass spectrometry, whose work has been pivotal in addressing urgent public health challenges. Her primary research focuses on developing high-throughput, mass spectrometry-based diagnostic platforms for infectious diseases. Dr. Fraga’s most notable contribution came during the COVID-19 pandemic, where she pioneered a rapid, targeted proteomics assay to detect the SARS-CoV-2 nucleoprotein in large clinical sample cohorts. This landmark 2020 study, which has garnered over 126 citations, demonstrated a scalable alternative to PCR testing, enabling faster population-wide screening during a global crisis. Her innovative approach not only accelerated pandemic response but also established a new paradigm for using proteomics in real-time disease surveillance. Beyond this, Dr. Fraga’s work continues to bridge the gap between advanced analytical chemistry and clinical diagnostics, making her a key voice in the fight against emerging pathogens. Her achievements highlight the power of interdisciplinary science in safeguarding public health.
Research Focus
Key Achievements
Top Papers
- 1